Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France

Ouzan, Denis; Larrey, Dominique; Guyader, Dominique; Remy, André‐Jean; Riachi, Ghassan; Héluwaert, Frédéric; Truchi, Régine; Combis, Jean‐Marc; Bailly, François; Rosa, Isabelle; Hézode, Christophe; Glorian-Petraud, Denise; Libert, O.; Ramroth, Heribert; Asselah, Tarik; Thiéfin, Gérard; Roulot, Dominique; Roche, Bruno; Leroy, Vincent; Dumortier, Jérôme; Thabut, Dominique; Pol, Stanislas

doi:10.1007/s10620-020-06234-1

Cited by 4 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pangenotypic regimens, sofosbuvir/velpatasvir or glecaprevir/ pibrentasvir, led to a new paradigm ('treat to screen') in the management of difficult-to-treat populations such as PWIDs. These treatments require minimal data before their initiation, have an excellent tolerance, a response rate greater than 95% 11,[25][26][27][28][29] and very few drug-to-drug interactions including OSTs. 30,31 All our PWIDs who began a brief treatment course of 8-12 weeks remained compliant especially thanks to the work of the addictology nurses.…”

Section: Availability Of Pangenotypic Treatmentsmentioning

confidence: 99%

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Debette-Gratien

François

Chevalier

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

According to the French recommendations, the elimination of the hepatitis C virus by 2025 could be a realistic public health goal. Screening policies are being intensified, and access to treatment is promoted for patients who escape the usual care pathway.The 'Scanvir' program is an original strategy based on dedicated screening days, as part of the 'test, treat and cure HCV' event in addiction care centers in a French region, during which innovative screening technologies (RDTs, FibroScan® and pointof-care HCV RNA testing) are brought on site and access to a multidisciplinary team is offered. A total of 392 patients attended the 67 regional Scanvir sessions: 31.6%were HCV Ab-positive and 66% of them were HCV RNA-positive. Treatment was initiated in 79.3% of the patients. RDTs were accepted by 62% of the PWIDs (including those who already knew their status) and FibroScan® by 99.5% of the patients. 80% of the viremic patients started their treatment on site and are now cured or still under treatment. Advanced fibrosis evaluated by FibroScan® (LSM > 8 KPa) was suspected in 13.4% and 14.1% of the global and the HCV population, respectively. Scanvir is an efficient strategy for HCV elimination based on dedicated days aimed at increasing cost-effectiveness and offering a multidisciplinary service while saving human care resources. It is an exportable strategy that also offers comprehensive screening of associated chronic liver diseases via the elastometry device and interviews.

show abstract

Section: Availability Of Pangenotypic Treatmentsmentioning

confidence: 99%

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Debette-Gratien

François

Chevalier

et al. 2023

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…In the 25 y since IFN-was launched for this reason in 1991, the management of chronic hepatitis C infection has undergone significant development [6]. Candidates for antiviral therapy are those with detectable HCV RNA in the serum, regardless of aminotransferase levels and grade or stage of cirrhosis [7].…”

Section: Introductionmentioning

confidence: 99%

Clinical Profile and Treatment Response to Sofosbuvir-Velpatasvir Regimen and Its Impact on the Quality of Life in Chronic Hepatitis C Patients

SINGH,

ASATI,

YADAV

2023

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Chronic Hepatitis C infection is one of the major global contributors to liver-related morbidity and mortality. Successful antiviral therapy with the direct-acting antiviral combination sofosbuvir-velpatasvir has shown to improve survival, liver-related outcomes, all-cause mortality, and even reverse fibrosis. We evaluated the treatment response of this regimen in terms of its impact on the Quality of life of patients during and after the therapy. Methods: This is an Observational, prospective, descriptive study of serologic HCV RNA-positive cases. Data on change in clinical, biochemical profile, and quality of life using 2 standardized questionnaires SF-36 and CLDQ was analyzed at baseline, 12 w from baseline, and 24 w after therapy cessation. Results: 62 out of the 87 patients registered during the study completed the desired study duration. 95% achieved sustained virological response (SVR) at 12 w and 100% at 24 w from baseline. Improved clinical profile with symptom resolution and change in the biochemical parameters and quality-of-life scores was statistically significant (P value-<0.001 and 0.005) at 12 w from baseline and 24 w after therapy cessation, respectively. Conclusion: Patients achieving SVR with sofosbuvir-velpatasvir have been shown to improve clinical profile with normalization in biochemical markers of liver disease, which is reflected in all the quality-of-life domains of SF-36 and CLDQ-HCV. However, long-term follow-up with larger sample size is required for improved study validity and to improve long-term liver-related outcomes.

show abstract

“…No entanto, desde 2011, após a introdução dos DAAs, também reconhecidos como tratamentos livres de IFN, o índice de RVS para DAAs é superior 90%(27). Em nosso coorte até o momento 61 pacientes receberam DAAs, dos quais 57 pacientes concluíram o tratamento, sendo que todos atingiram RSV.…”

unclassified

Hepatite C em pacientes com doença hemorrágica hereditária

Maria Foschi

View full text Add to dashboard Cite

show abstract

Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France

Cited by 4 publications

References 49 publications

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days

Clinical Profile and Treatment Response to Sofosbuvir-Velpatasvir Regimen and Its Impact on the Quality of Life in Chronic Hepatitis C Patients

Hepatite C em pacientes com doença hemorrágica hereditária

Contact Info

Product

Resources

About